See what's trending this week...
Companies: OPM, SIXH, ABZA, AVO, AGY, APH, ARBB, AVCT, BNO, BUR, CMH, CLIG, COS, D4T4, DNL, EQLS, EVG, GTLY, GDR, HMLH, IMO, INL, KOOV, MCL, MUR, NSF, NXR, OXB, PHP, RE/, REDX, RDT, SCLP, SEE, SCE, TRX, TON, VAL, YGEN
Automotive DMS taking off | Cenkos, 26 Jun
"It is becoming increasingly clear that all global automotive centres will implement driver monitoring systems (DMS) on a large scale in the early 2020's. We believe that Seeing Machines currently has a market leading, defensible position with a scalable offering, as demonstrated by recent design wins..."
Landmark data deals secure strong H2 | finnCap, 26 Jun
"The prelims reveal that H2 earnings were even stronger than expected; the two largest contracts in the company’s history helped to lift revenue by 14% and underlying PBT to £5.1m, up 22% YoY and 6% ahead of forecast. Adj. EPS and dividend rose 10% and 11% respectively (building on 19% and 13% growth LY). The company is now well established in the data management industry, enabling financial services and consumer enterprises to power their AI and advanced analytics with its innovative data platform solutions..."
Strategy successfully delivered | Cenkos, 27 Jun
"Today's trading update highlights the group's newfound scale as a multi-product/brand lender, with FY18E revenues expected to be £30m (+77% YoY) and reported PBT set to be in-line with our £7.7m forecast (+89% YoY). This confirms the stronger H2/18E delivery as expected and the continuation of material double-digit organic growth over the full year..."
by Hardman & Co, 29 June
1pm | Abzena | Advanced Oncotherapy | Allergy Therapeutics | Alliance Pharma | Arbuthnot Banking | Avacta | Bionomics | Burford Capital | Chamberlin | City Of London Investment Group | Collagen Solutions | Diurnal | Evgen Pharma | Gateley | Genedrive | Inland Homes | Koovs | Morses Club | Murgitroyd | Non-Standard Finance | Oxford Biomedica | Premaitha Health | Primary Health Properties | R.E.A | Redx Pharma | Scancell | Surface Transforms | 600 Group | Tissue Regenix | Titon | ValiRx
"We have analysed every IPO on the London Stock Exchange (LSE) between January 2015 and February 2018. Our analysis proves that, as expected, liquidity does dry up after float. The scale varies between markets and sectors..."
Growth opportunities ahead | Cenkos, 26 Jun
"Revenues almost doubled last year, in part through the acquisition of Integritie. Management confidence is high and its efforts to improve the quality of business should mean greater predictability going forward. The stock is trading on an EV/Sales ratio at a sharp discount to the sector of 1.0x and there are genuine growth opportunities ahead..."
Launch of Fair Everywhere | Cenkos, 27 Jun
"FairFX has announced the launch of Fair Everywhere, its global business current account with full day-to-day domestic business banking services and international forex payments and revenues, with a simple £50/month all-inclusive account fee that works out to up to 60% average cost savings versus the high-street banks. Existing FairFX Business customers will be given priority access for the first 1,000 customers..."
Good final results | finnCap, 26 Jun
"The business model continues to deliver a consistent growth profile and the company remains well placed to benefit from any further tightening of industry legislation. We raise our target price to 53p, implying potential share price upside of 61%..."
FY results | Whitman Howard, 27 Jun
"IMIMobile (Buy PT 331p) has announced FY results for the year to March today, which follow on from the trading statement on the 24th April. We are not changing our published forecasts and introduce, a March 2020E for the first time, with a revenue forecast of £133m and Adj EBITDA of £16.9m. Our price target is now 331p, based on our 2020 estimates, and our view that underlying margins will grow after a period of investment..."
Explicit growth aspirations | Edison, 29 Jun
"Variable underlying markets did not prevent Norcros from delivering both organic and acquired progress in FY18. Moreover, a new target of almost doubling revenue by 2023 has been set with ROCE sustained above 15%+. Share price movements suggest that the market is starting to give credit for management’s achievements. Performance will be measured against the strategic plan and we believe that a further re-rating is likely..."